NPORT-EX 2 NPORT_2QKB_98112527_1021.htm

 

Schedule of Investments (unaudited)

 iShares® Evolved U.S. Healthcare Staples ETF
October 31, 2021 (Percentages shown are based on Net Assets)

 

Security  Shares   Value 
         
Common Stocks          
           
Biotechnology — 3.6%          
Amgen Inc.   327   $67,679 
Bio-Rad Laboratories Inc., Class A(a)   170    135,096 
Exact Sciences Corp.(a)   1,687    160,636 
Guardant Health Inc.(a)   798    93,198 
Illumina Inc.(a)   1,768    733,826 
Myriad Genetics Inc.(a)   782    24,062 
NeoGenomics Inc.(a)   1,256    57,776 
Pacific Biosciences of California Inc.(a)   1,208    31,988 
Twist Bioscience Corp.(a)   271    32,195 
Veracyte Inc.(a)   595    28,489 
         1,364,945 
Commercial Services — 0.4%          
AMN Healthcare Services Inc.(a)   426    42,046 
Bright Horizons Family Solutions Inc.(a)   272    45,152 
Grand Canyon Education Inc.(a)   257    20,483 
Progyny Inc.(a)   446    27,398 
Strategic Education Inc.   85    5,798 
         140,877 
Computers — 0.1%          
Maximus Inc.   361    30,530 
           
Electrical Components & Equipment — 0.1%          
Novanta Inc.(a)   305    52,631 
           
Electronics — 1.1%          
Agilent Technologies Inc.   1,890    297,656 
OSI Systems Inc.(a)   81    7,542 
Waters Corp.(a)   307    112,838 
         418,036 
Environmental Control — 0.1%          
Stericycle Inc.(a)   237    15,860 
           
Food Service — 0.0%          
Healthcare Services Group Inc.   611    11,725 
           
Health Care - Products — 48.4%          
10X Genomics Inc., Class A(a)   222    35,802 
Abbott Laboratories   23,257    2,997,595 
ABIOMED Inc.(a)   527    174,985 
Adaptive Biotechnologies Corp.(a)   494    16,505 
Align Technology Inc.(a)   360    224,773 
AngioDynamics Inc.(a)   408    11,669 
AtriCure Inc.(a)   408    30,624 
Avanos Medical Inc.(a)   340    10,724 
Avantor Inc.(a)   1,887    76,197 
Axogen Inc.(a)   187    2,841 
Baxter International Inc.   3,196    252,356 
Bio-Techne Corp.   287    150,288 
Boston Scientific Corp.(a)   18,108    780,998 
Bruker Corp.   646    51,874 
Cardiovascular Systems Inc.(a)   357    12,524 
CareDx Inc.(a)   461    23,511 
Cooper Companies Inc. (The)   561    233,892 
Cutera Inc.(a)   119    5,117 
Danaher Corp.   5,375    1,675,764 
DENTSPLY SIRONA Inc.   1,427    81,639 
Edwards Lifesciences Corp.(a)   8,211    983,842 
Envista Holdings Corp.(a)   966    37,771 
Glaukos Corp.(a)   238    10,879 
Security  Shares   Value 
         
Health Care - Products (continued)          
Globus Medical Inc., Class A(a)   1,003   $77,401 
Haemonetics Corp.(a)   408    28,034 
Henry Schein Inc.(a)   1,220    93,147 
Hill-Rom Holdings Inc.   614    95,109 
Hologic Inc.(a)   2,530    185,474 
ICU Medical Inc.(a)   170    39,802 
IDEXX Laboratories Inc.(a)   677    450,977 
Inspire Medical Systems Inc.(a)   308    83,031 
Insulet Corp.(a)   816    252,976 
Integer Holdings Corp.(a)   255    22,955 
Integra LifeSciences Holdings Corp.(a)   714    47,452 
Intersect ENT Inc.(a)   187    5,043 
Intuitive Surgical Inc.(a)   4,475    1,616,057 
iRhythm Technologies Inc.(a)   320    22,445 
LeMaitre Vascular Inc.   187    9,726 
LivaNova PLC(a)   506    38,820 
Masimo Corp.(a)   629    178,347 
Medtronic PLC   16,578    1,987,039 
Merit Medical Systems Inc.(a)   578    38,876 
NanoString Technologies Inc.(a)   388    18,740 
Natera Inc.(a)   883    101,165 
Neogen Corp.(a)   306    12,947 
Nevro Corp.(a)   272    30,937 
Novocure Ltd.(a)   581    59,593 
NuVasive Inc.(a)   612    32,656 
Omnicell Inc.(a)   339    60,393 
OraSure Technologies Inc.(a)   663    7,074 
Orthofix Medical Inc.(a)   203    7,304 
Patterson Companies Inc.   682    21,319 
Penumbra Inc.(a)   479    132,467 
PerkinElmer Inc.   801    141,689 
Quanterix Corp.(a)   268    13,563 
Quidel Corp.(a)   428    56,826 
ResMed Inc.   1,682    442,215 
Shockwave Medical Inc.(a)   256    54,707 
Silk Road Medical Inc.(a)   305    17,907 
STAAR Surgical Co.(a)   458    54,255 
STERIS PLC.   491    114,766 
Stryker Corp.   4,164    1,107,915 
Tandem Diabetes Care Inc.(a)   580    79,071 
Teleflex Inc.   531    189,535 
Thermo Fisher Scientific Inc.   3,095    1,959,352 
Zimmer Biomet Holdings Inc.   2,027    290,104 
         18,161,381 
Health Care - Services — 24.4%          
Acadia Healthcare Co. Inc.(a)   846    52,452 
Addus HomeCare Corp.(a)   138    12,903 
Amedisys Inc.(a)   427    72,308 
Anthem Inc.   1,217    529,553 
Centene Corp.(a)   6,135    437,057 
Charles River Laboratories International Inc.(a)   153    68,648 
Chemed Corp.   120    57,870 
DaVita Inc.(a)   887    91,574 
Encompass Health Corp.   1,391    88,412 
Ensign Group Inc. (The)   325    25,353 
HCA Healthcare Inc.   3,329    833,781 
Humana Inc.   1,246    577,097 
ICON PLC(a)(b)   98    28,104 
Invitae Corp.(a)   1,767    46,826 
IQVIA Holdings Inc.(a)   1,123    293,575 


 

1

 

Schedule of Investments (unaudited) (continued)

 iShares® Evolved U.S. Healthcare Staples ETF
October 31, 2021 (Percentages shown are based on Net Assets)

 

Security  Shares   Value 
         
Health Care - Services (continued)          
Laboratory Corp. of America Holdings(a)   1,022   $293,335 
LHC Group Inc.(a)   358    48,183 
Magellan Health Inc.(a)   108    10,242 
MEDNAX Inc.(a)   1,141    31,069 
Medpace Holdings Inc.(a)   121    27,413 
ModivCare Inc.(a)   120    19,532 
Molina Healthcare Inc.(a)   140    41,401 
OPKO Health Inc.(a)   3,421    12,966 
Quest Diagnostics Inc.   1,448    212,538 
R1 RCM Inc.(a)   830    18,011 
Select Medical Holdings Corp.   1,496    49,697 
Syneos Health Inc.(a)   204    19,041 
Teladoc Health Inc.(a)   970    145,102 
Tenet Healthcare Corp.(a)   1,241    88,930 
U.S. Physical Therapy Inc.   204    22,003 
UnitedHealth Group Inc.   10,391    4,784,744 
Universal Health Services Inc., Class B   849    105,361 
         9,145,081 
Household Products & Wares — 0.2%          
Church & Dwight Co. Inc.   967    84,477 
           
Pharmaceuticals — 16.3%          
AbbVie Inc.   3,092    354,560 
AmerisourceBergen Corp.   1,160    141,543 
Bausch Health Companies Inc.(a)   950    26,676 
Becton Dickinson and Co.   3,403    815,325 
Cardinal Health Inc.   2,686    128,418 
Cigna Corp.   2,908    621,178 
Covetrus Inc.(a)   582    11,750 
CVS Health Corp.   11,921    1,064,307 
Dexcom Inc.(a)   1,067    664,965 
Eli Lilly & Co.   207    52,735 
Johnson & Johnson   9,233    1,503,871 
McKesson Corp.   1,204    250,287 
Option Care Health Inc.(a)   902    24,652 
Owens & Minor Inc.   580    20,810 
Perrigo Co. PLC   252    11,378 
Pfizer Inc.   7,685    336,142 
Premier Inc., Class A   1,256    48,921 
Zoetis Inc.   133    28,755 
         6,106,273 
Real Estate Investment Trusts — 1.0%          
Healthpeak Properties Inc.   1,307    46,412 
Medical Properties Trust Inc.   3,927    83,763 
National Health Investors Inc.   224    12,047 
Security  Shares   Value 
         
Real Estate Investment Trusts (continued)          
Omega Healthcare Investors Inc.   882   $25,895 
Physicians Realty Trust.   1,394    26,500 
Sabra Health Care REIT Inc.   1,360    19,244 
Ventas Inc.   1,390    74,184 
Welltower Inc.   1,102    88,601 
         376,646 
Retail — 0.5%          
National Vision Holdings Inc.(a)   324    19,971 
Walgreens Boots Alliance Inc.   3,640    171,153 
         191,124 
Software — 0.8%          
Allscripts Healthcare Solutions Inc.(a)   1,324    18,245 
Cerner Corp.   2,566    190,628 
Change Healthcare Inc.(a)   1,679    36,149 
Evolent Health Inc., Class A(a)   880    25,757 
Phreesia Inc.(a)   242    17,071 
Tabula Rasa HealthCare Inc.(a)   170    4,615 
         292,465 
Total Common Stocks — 97.0%          
(Cost: $28,254,327)       36,392,051 
           
Short-Term Investments          
           
Money Market Funds — 3.0%          
BlackRock Cash Funds: Institutional, SL Agency Shares, 0.05%(c)(d)(e)   28,407    28,421 
BlackRock Cash Funds: Treasury, SL Agency Shares, 0.00%(c)(d)   1,096,000    1,096,000 
         1,124,421 
Total Short-Term Investments — 3.0%          
(Cost: $1,124,421)       1,124,421 
           
Total Investments in Securities — 100.0%          
(Cost: $29,378,748)       37,516,472 
           
Other Assets, Less Liabilities — (0.0)%       (6,586)
           
Net Assets — 100.0%      $37,509,886 

 

(a)Non-income producing security.

(b)All or a portion of this security is on loan.
(c)Affiliate of the Fund.
(d)Annualized 7-day yield as of period end.
(e)All or a portion of this security was purchased with the cash collateral from loaned securities.


 

2 

 

 

Schedule of Investments (unaudited) (continued)

 iShares® Evolved U.S. Healthcare Staples ETF
October 31, 2021

 

Affiliates

 

Investments in issuers considered to be affiliate(s) of the Fund during the period ended October 31, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer  Value at
07/31/21		   Purchases
at Cost		   Proceeds
from Sales		   Net Realized
Gain (Loss)		   Change in
Unrealized
Appreciation
(Depreciation)		   Value at
10/31/21		   Shares
Held at
10/31/21		   Income   Capital
Gain
Distributions
from
Underlying
Funds		 
BlackRock Cash Funds: Institutional, SL Agency Shares  $175,635   $—   $(147,214)(a)  $2   $(2)  $28,421    28,407   $13(b)  $— 
BlackRock Cash Funds: Treasury, SL Agency Shares   1,006,000    —    —         —    1,096,000    1,096,000    14    — 
                  $2   $(2)  $1,124,421        $47   $— 

 

(a)Represents net amount purchased (sold).
(b)All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

 

Fair Value Measurements

 

Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows: 

●Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that each Fund has the ability to access;

●Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs); and
●Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the BlackRock Global Valuation Methodologies Committee’s (the “Global Valuation Committee’s”) assumptions used in determining the fair value of financial instruments).

 

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Global Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds. There may not be a secondary market, and/or there are a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Fund’s policy regarding valuation of financial instruments, refer to its most recent financial statements.

 

The following table summarizes the Fund’s financial instruments categorized in the fair value hierarchy. The breakdown of the Fund’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

   Level 1   Level 2   Level 3   Total 
Investments                    
Assets                    
Common Stocks  $36,392,051   $—   $—   $36,392,051 
Money Market Funds   1,124,421    —    —    1,124,421 
   $37,516,472   $—   $—   $37,516,472 

 

Portfolio Abbreviations - Equity

 

REITReal Estate Investment Trust

 

3